On November 20, Guardant Health Inc. falls 5.69% in Pre-Market Trading, trading at $143.07/share, with turnover of $373,200.
The clearest catalyst in recent public information is continued investor focus on the company’s recently priced and settled $500 million zero-coupon convertible senior notes due 2032, with the market weighing potential future conversion dilution and financing overhang.
Company disclosures showed expected net proceeds of about $538.3 million if the full option is exercised. Guardant Health Inc. said about $501.7 million would be used to repurchase roughly $395.2 million principal amount of its 2027 zero-coupon convertible notes, while the remaining proceeds, together with cash on hand, would fund about $51.7 million of capped call transactions intended to offset future dilution and extend debt maturities.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments